Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges.
10.1007/s11684-023-1050-6
- Author:
Zhichen JIANG
1
;
Xiaohao ZHENG
2
;
Min LI
3
;
Mingyang LIU
4
Author Information
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
3. Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Min-Li@ouhsc.edu.
4. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. liumy@cicams.ac.cn.
- Publication Type:Review
- Keywords:
cancer screening;
molecular alterations;
pancreatic cancer;
precancerous lesion;
single cell;
therapy resistance
- MeSH:
Humans;
Pancreatic Neoplasms/therapy*;
Prognosis;
Pancreas/pathology*;
Genetic Predisposition to Disease;
Genomics
- From:
Frontiers of Medicine
2023;17(6):1135-1169
- CountryChina
- Language:English
-
Abstract:
Pancreatic cancer, notorious for its late diagnosis and aggressive progression, poses a substantial challenge owing to scarce treatment alternatives. This review endeavors to furnish a holistic insight into pancreatic cancer, encompassing its epidemiology, genomic characterization, risk factors, diagnosis, therapeutic strategies, and treatment resistance mechanisms. We delve into identifying risk factors, including genetic predisposition and environmental exposures, and explore recent research advancements in precursor lesions and molecular subtypes of pancreatic cancer. Additionally, we highlight the development and application of multi-omics approaches in pancreatic cancer research and discuss the latest combinations of pancreatic cancer biomarkers and their efficacy. We also dissect the primary mechanisms underlying treatment resistance in this malignancy, illustrating the latest therapeutic options and advancements in the field. Conclusively, we accentuate the urgent demand for more extensive research to enhance the prognosis for pancreatic cancer patients.
